A Phase Ib/II, Mulicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma

Trial Profile

A Phase Ib/II, Mulicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Encorafenib (Primary) ; Ribociclib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 27 Jul 2016 Status changed from completed to discontinued.
    • 22 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 15 Oct 2014 Planned End Date changed from 1 Jan 2016 to 1 Feb 2016, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top